ME 1207, a new oral cephalosporin, was administered to 9 patients with superficial purulent diseases. The clinical efficacy, bacteriological effects and safety were evaluated. Clinical efficacy was excellent in 1, good in 7 and fair in 1 patient. No side effects or abnormal changes in laboratory findings were observed.
